Alzheimer’s disease: Promising new drug shown to reduce molecular markers and symptoms

    0

    [ad_1]

    Alzheimer’s disease is a progressive neurodegenerative condition which is associated with the formation of abnormal protein structures in the brain. Scientists think that these structures lead to nerve cell death and diminishing brain function. A new drug is said to help reduce molecular molecules which occur in the disease with promising results.

    What are the early signs of Alzheimer’s disease?

    Memory loss

    Poor judgment leading to bad decisions

    Loss of spontaneity and sense of initiative

    Taking longer to complete normal daily tasks

    Repeating questions

    Trouble handling money and paying bills

    Wandering and getting lost

    Losing things or misplacing them in odd places

    Mood and personality changes

    Increased anxiety and/or aggression

     

    Gantenerumab is a fully human antibody, a protein that is designed to interact with a specific target, said Alzheimer’s News Today.

    The site added: “Once gantenerumab binds to beta-amyloid, it is thought to disassemble the plaques that have formed and remove beta-amyloid by stimulating phagocytosis, a process where a cell takes a certain molecule inside itself and digests it.

    “Researchers hope that reducing beta-amyloid will benefits patients, potentially slowing the progression of Alzheimer’s disease.”

    “These biomarker results suggest that gantenerumab had a favourable impact on the target and downstream markers of Dominantly Inherited Alzheimer’s Disease,” said Dr Rachelle Doody, global head of neurodegeneration at Roche and Genentech.

    She added: “We support the continued scientific investigation of gantenerumab in Washington University’s exploratory, open-label extension study to build on learnings from DIAN-TU-001 and are grateful to be a part of this close collaboration between industry, academia and patients as we continue to tackle the complex challenge of Alzheimer’s disease.

    “We are encouraged by the advancements being made and look forward to continued progress for people with Alzheimer’s disease.”



    [ad_2]

    Previous articleEngland players making Gareth Southgate complaint ahead of Czech Republic Euro 2020 clash
    Next articleLook who's come around! US bank that repeatedly bashed Brexit makes huge London investment

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here